文献速递血栓与止血造血干细胞移植与细胞治疗

阻断CD28-B7共刺激信号轴实现AAV8基因载体重复给药

Blockade of the costimulatory CD28-B7 family signal axis enables repeated application of AAV8 gene vectors.
PubMed 文献 · J Thromb Haemost · 2020-03-02

AAV8基因治疗因首次治疗后产生抗AAV8免疫而只能单次应用。研究开发了以CTLA4-IgG(阿巴西普)为基础的预防性免疫抑制方案,用于人凝血因子IX载体(目标剂量约5×10^11 vg/kg)。临床前模型显示,初次基因治疗期间短暂使用阿巴西普可抑制AAV8特异性细胞和体液应答,从而允许FIX重复给药;数据还提示该方案可抑制第二次高剂量(4×10^12 vg/kg)后的抗AAV8中和抗体应答,使重复给药至该高剂量成为可能。

要点

  • CTLA4-IgG阻断CD28信号可抑制AAV8特异性中和抗体和T细胞应答。
  • 临床前模型中初次治疗期间短暂免疫抑制允许FIX载体重复给药。
  • 该方案或可支持第二次给药剂量高达4×10^12 vg/kg。

核心结论

  • CTLA4-IgG(阿巴西普)阻断CD28-B7共刺激信号轴可在临床前模型中抑制抗AAV8免疫并实现AAV8基因载体重复给药。

研究设计与样本

  • 临床前模型研究,评估人凝血因子IX(FIX)AAV8载体初次给药目标剂量约5×10^11 vg/kg及第二次更高剂量4×10^12 vg/kg。

主要发现

  • 初次人FIX基因治疗期间短暂使用阿巴西普有效抑制AAV8特异性细胞和体液应答,允许FIX重复给药。
  • 数据提示该方案通过抑制第二次更高剂量(4×10^12 vg/kg)后的抗AAV8中和抗体应答,可支持重复给药至该高剂量。
  • CTLA4-IgG阻断CD28介导信号可能抑制AAV8特异性细胞毒性CD8 T细胞应答。

临床怎么用

  • 使用已批准药物阿巴西普的重复给药方案可便捷用于临床试验,为接受AAV8基因治疗的患者提供安全有效的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adeno-associated virus serotype 8 (AAV8) gene therapy has shown efficacy in several clinical trials and is considered a highly promising technology to treat monogenic diseases such as hemophilia A and B. However, a major drawback of AAV8 gene therapy is that it can be applied only once because anti-AAV8 immunity develops after the first treatment. Readministration may be required in patients who are expected to need redosing, eg, due to organ growth, or to boost suboptimal expression levels, but no redosing protocol has been established. We have developed a preventive immune-suppressive protocol for a human factor IX (FIX) vector with an intended dose of ~5 × 1011 vg/kg that inhibits the development of anti-AAV8 neutralizing-antibody (NAb) responses and anti-AAV8 T-cell responses using CTLA4-IgG (abatacept). In a preclinical model, transient treatment with abatacept during initial human FIX gene therapy efficiently inhibited the generation of AAV8-specific cellular and humoral responses, and thus permitted redosing of FIX. Furthermore, our data suggest that by suppression of anti-AAV8 NAb responses after the second higher dose (4 × 1012 vg/kg) this protocol can be used to enable redosing up to such high doses. An additional advantage of CTLA4-IgG blocking CD28-mediated signals is its potential suppression of AAV8-specific cytotoxic CD8 T-cell responses, which are believed to kill transduced hepatocytes and might interfere with a successful readministration. Redosing protocols using approved drugs would be beneficial for patients because they could effortlessly be applied in clinical trials and enable safe and efficient treatment options for patients undergoing AAV8 gene therapy.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Frentsch M, Japp AS, Dingeldey M, et al. Blockade of the costimulatory CD28-B7 family signal axis enables repeated application of AAV8 gene vectors. J Thromb Haemost. 2020. PMID: 32011092. doi:10.1111/jth.14757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。